Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
186,616,143
-
Total 13F shares
-
14,436,164
-
Share change
-
+9,840,912
-
Total reported value
-
$5,809,652
-
Price per share
-
$0.40
-
Number of holders
-
34
-
Value change
-
+$3,945,317
-
Number of buys
-
15
-
Number of sells
-
8
Institutional Holders of Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP) as of Q4 2023
As of 31 Dec 2023,
Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,436,164 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, SABBY MANAGEMENT, LLC, Alyeska Investment Group, L.P., MARSHALL WACE, LLP, Rosalind Advisors, Inc., Altium Capital Management LP, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, and ACADIAN ASSET MANAGEMENT LLC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.